Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Oxford-Harrington Rare Disease Centre is redoubling efforts to develop a therapeutics programme for Friedreich’s Ataxia.

Researchers working in a laboratory with medical equipment

Friedreich’s Ataxia (FA) is a debilitating, life-shortening, degenerative neuromuscular rare disorder, with onset during childhood. Despite high levels of existing medical research around FA, significant further progress is needed to advance new treatments.

The Oxford-Harrington Rare Disease Centre (OHC) has the expertise and capability to contribute to the major effort underway aimed at developing effective treatments for FA in the near future. The OHC combines the University of Oxford and the Harrington Discovery Institute's world-leading strengths in research and therapeutics development. The OHC was formed to set the science and innovation agenda, driving cutting-edge rare disease breakthroughs to address the unmet need in rare disease across the globe and to deliver major clinical impact for patients. Friedreich’s Ataxia is a compelling initial focus area given this goal.

The OHC has adopted FA as a priority area within its neurological disorders theme. Ultimately, the OHC hopes to participate meaningfully in developing a therapy to treat or potentially cure FA through coordinated research efforts, leveraging the full strengths of the University of Oxford and the Harrington Discovery Institute, and externally with leading institutions across the world to focus efforts on therapeutic interventions with immediate potential.

OHC will be building on the long history of important contributions to the FA field by Oxford researchers. As a first step in this new journey, with the support of EndFA, a philanthropic partner focused on FA, the OHC has recruited a new Research Facilitator in Friedreich’s Ataxia. Dr Geoffrey Denwood joined the OHC at the University of Oxford site in April 2021, and will dedicate his time and expertise into coordinating the activities of the OHC in FA. Dr Denwood will evaluate the current status of FA translational research and therapeutics development locally and globally, then work to fund and implement an OHC programme harnessing the best expertise and most promising therapeutic opportunities.

For more information please contact info@oxfordharrington.org.

Similar stories

NHS garden in full bloom at RHS Chelsea Flower Show

The sun was shining for the RHS Chelsea Flower show press day earlier this week. One garden in particular bloomed particularly brightly, with the 'Finding Our Way: An NHS Tribute Garden' getting plenty of attention.

University of Oxford launches Podium Analytics Institute for Youth Sports Medicine and Technology

Oxford University has been selected as the home of the new Podium Analytics Institute for Youth Sports Medicine and Technology. This will be the world’s first academic Institute focused on young athletes’ safety and lifelong health and will combine Oxford’s longstanding tradition in sports and education with the very best of science, medicine, and technology.

QCovid highly commended for ‘best use of technology in Patient Safety’ at the 2021 HSJ Patient Safety Awards

Professor Julia Hippisley-Cox and her team in Nuffield Department of Primary Care Health Sciences have been Highly Commended in the ‘Best use of technology in Patient Safety’ category for the QCovid risk calculator at this year’s Health Service Journal Patient Safety Awards.

New guidelines to improve reporting standards of studies that investigate causal mechanisms

Researchers in the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) have developed a new set of guidelines for reporting mediation analyses in health research.

Prestigious award for Oxford professor's diabetes work

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.